SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Polyrizon Completes Enrollment of 120 Patients in U.S. NASARIX Study

All 120 planned participants were randomized across five U.S. clinical sites in the study of the NASARIX allergy blocker.

PLRZ

Related stories